Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474589 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
A Phase 3 study, sponsored by SIGA Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
NCT02474589 is a Phase 3 study that has completed, run by SIGA Technologies. The registered enrollment target is 449 participants.
The verdict
NCT02474589, a Phase 3 study, has completed, sponsored by SIGA Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
Study Summary
Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
Interventions
- OTHER Placebo
- DRUG tecovirimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2015-06-19 |
| Est. Completion | 2016-08-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02474589
The ClinicalTrials.gov registry entry for NCT02474589 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SIGA Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02474589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02474589 about?
NCT02474589 is a clinical study titled "A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat". Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
What is the current status of trial NCT02474589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2015-06-19. Estimated completion is 2016-08-24.
What interventions are being tested in trial NCT02474589?
The interventions under investigation include: Placebo (OTHER), tecovirimat (DRUG).
Who is sponsoring clinical trial NCT02474589?
This trial is sponsored by SIGA Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.